aTyr Pharma Inc (LIFE.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|63||2005||Independent Chairman of the Board|
|57||2015||Chief Executive Officer, Director|
|40||2017||Senior Vice President - Finance|
|58||2016||Senior Vice President - Research|
|58||2016||Senior Vice President, Product Programs and Planning|
- BRIEF-Atyr Pharma files for resale of up to 23.6 mln shares of common stock by selling stockholders - SEC Filing
- BRIEF-Viking Global Investors reports 9.5 pct passive stake in aTyr Pharma
- BRIEF-Atyr Pharma qtrly net loss per share $0.51
- BRIEF-ATyr pharma enters into first amendment to loan and security agreement
- BRIEF-aTyr Pharma announces qtrly net loss per share, basic and diluted $0.56